Cardiovascular biotech Kardigan filed for a Nasdaq initial public offering to fund development of a phase 2b/3 cardiac myosin activator, danicamtiv, plus additional late-stage opportunities. The company’s pipeline includes ataciguat for calcific aortic valve stenosis and tonlamarsen as a liver-directed antisense approach for patients recently hospitalized for hypertension. Kardigan’s danicamtiv program traces roots to MyoKardia’s myosin inhibitor experience, where mavacamten (Camzyos) became an approved therapy after Bristol Myers Squibb’s acquisition. Kardigan reported prior investor interest after launching with a $300 million Series A and later raising an additional $254 million. The IPO filing signals continued market appetite for clinical-stage cardiovascular platforms, especially those backed by prior asset validation and differentiated mechanistic positioning.